ANI Pharmaceuticals Makes $576 Million Offer to Acquire Egetis Therapeutics

04:16 AM EST, 11/05/2026 (MT Newswires) -- ANI Pharmaceuticals (ANIP) is making a 5.6 billion Swedish kronor ($576 million) bid to acquire Egetis Therapeutics, a commercial-stage pharmaceutical company focused on therapies for patients with rare diseases with significant unmet medical need, the company said Thursday. Under the terms of the recommended public offer, ANI would pay SEK 11.25 per share, representing a 27% premium to Egetis' 60-day volume-weighted average price, the company said. The acquisition includes proceeds from a $190 million sale of Egetis' Rare Pediatric Disease Priority Review Voucher, the company said. Egetis' board unanimously recommended the offer, while shareholders representing approximately 42% of its outstanding shares have agreed to accept it, ANI said. The offer is subject to customary closing conditions, including acceptance by shareholders holding at least 90% of Egetis' outstanding shares and regulatory approvals. The acceptance period is expected to begin around Nov. 20 and end around Dec. 18, ANI said.